In our new scoping review, we explored the impact of clinical trial data-sharing initiatives. We looked at various outcome domains...

Our essay "An open science pathway for drug marketing authorization -Registered drug approval" won the "Reimagine Biomedical Research for...

In a recent letter, as part of an international group (Enrico Bucci, Johannes Berkhof, André Gillibert, Gowri Gopalakrishna, Raffaele A...

On April 1st, 2021, our group and colleagues from the Ludwig-Maximilians-Universität München (Faculty of Medicine) organized a workshop...

We have just registered our new protocol on the Open Science Framework. We are planning a new study about conflict of interests in...

Again some good news! On April the 1st this year, our group and colleagues from the Ludwig-Maximilians-Universität München (Faculty of...

Finally some good news in 2021 ! On January 19th this year, our group and colleagues from the Ludwig-Maximilians-Universität München...

“Funders’ data-sharing policies in therapeutic research: a survey of commercial and non-commercial funders” is the new article, from the...

This story is about Artemisia and two very "interesting" (or should I say infamous) studies. 1/ Well, read this paper: "Artemisia annua...

Taking advantage of the many good things pre print servers offer, and in a spirit of open science, we wrote a peer review with Andre...

"Data-sharing recommendations in biomedical journals and Randomized Controlled Trials: an audit of journals following the ICMJE...

We hypothesize in our projects that re-analyses of a random sample of unselected Randomised Controlled Trials will result in a good...

In mid-february our team made its way to the 3 day REWARD EQUATOR conference, which was hosted by the BIH Quest Center in Berlin,...

Our new paper, "The evidence base for psychotropic drugs approved by the European Medicines Agency [EMA]: a meta-assessment of all...

Reproducibility in Therapeutic Research (ReITheR) is a research program funded by the French Agence Nationale de la Recherche. The team...